RC
ONCY

Rovin Capital’s Oncolytics Biotech ONCY Stock Holding History

Rovin Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,620
Closed -$29K – 205
2025
Q3 		$29K Hold
20,620
– – 0.01% 193
2025
Q2 		$16K Hold
20,620
– – ﹤0.01% 187
2025
Q1 		$11K Hold
20,620
– – ﹤0.01% 177
2024
Q4 		$19K Hold
20,620
– – 0.01% 162
2024
Q3 		$18K Buy
+20,620
New +$20.2K 0.01% 169

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Rovin Capital's ONCY Position: Q4 2025 in Review

Rovin Capital sold out of Oncolytics Biotech (ONCY) in Q4 2025, closing a stake of 20,620 shares — an estimated $29K sold.

Rovin Capital first reported a position in ONCY in Q3 2024 and held it in 5 quarters. The position peaked at $29K in Q3 2025. 61 funds tracked by Wall St. Rank hold ONCY as of Q4 2025.

  • Rovin Capital reported no remaining Oncolytics Biotech position as of Q4 2025 after selling out during the quarter.
  • Rovin Capital sold 20,620 Oncolytics Biotech shares in Q4 2025, an estimated $29K.
  • Rovin Capital first reported a position in Oncolytics Biotech in Q3 2024 and held it in 5 quarters.
  • Rovin Capital's Oncolytics Biotech position peaked at $29K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2025.

Based on Rovin Capital's 13F filing for Q4 2025, filed 9 Feb 2026.